383907-43-5

IC50: 0.21 μM (Cdc25B2)

NSC 663284 (3-100μM; 48 hours) has a mean IC ₅₀ value in the NCI 60 Cell human tumor panel of 1.5 ± 0.6 μM, has IC ₅₀ values of 0.2 μM in human breast cancer MDA-MB-435 and MDA-N cells, has an IC ₅₀ value of 1.7 μM in human breast MCF-7 cells in culture. NSC 663284 has relative IC ₅₀ values for Cdc25B2 (IC ₅₀ =0.21 μM) are 20- and 450-fold lower than for VHR (IC ₅₀ =4.0 μM) or PTP1B (IC ₅₀ >4.0 μM), respectively.

NSC 663284 (intravenous injection; 2, 3, and 5mg/kg) inhibits the growth of subcutaneous human colon HT29 xenografts in SCID mice. After a single dose of 5 mg/kg, NSC 663284 is not detectable in plasma or tissues beyond 5 min. Following NSC 663284 treatment of tumor-bearing SCID mice, reduces glutathione concentrations in HT29 tumor are decreased to a greater extent and remained decreased for longer than the reduced glutathione concentrations in liver and kidneys.